PhRMA
OCTOBER 27, 2022
PhRMA is proud to announce the release of its first ever chart pack on health equity. This chart pack contains information on health equity in three sections: (1) A Snapshot of Health Disparities in America, (2) Inequities in Access to Screenings and Medicines Allow Health Disparities to Persist, and (3) PhRMA’s Commitment to Building a More Equitable Health Care System for All.
Drug Topics
OCTOBER 27, 2022
Drug Topics® is joined by Dr. Alex Capano, Chief Science Officer at Ananda professional to discuss what CBD is used for mental health, where research should go next, and how to ensure that patients are getting effective CBD products.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
OCTOBER 27, 2022
Although clinicians cited lack of time as a reason for not using patient-reported outcomes, patients with HIV viewed their use very positively.
Drug Topics
OCTOBER 27, 2022
COVID-19 bivalent booster uptake has been very sluggish, even though the booster provides better protection against newer variants. What can pharmacists and their teams do to improve booster rates?
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
OCTOBER 27, 2022
Phase 2 APPLY-PNH trial shows positive results superiority vs anti-C5 treatment in adult patients with PNH with residual anemia despite prior therapy.
Drug Topics
OCTOBER 27, 2022
Offering immunization services at the pharmacy promotes public health and strengthens patient-pharmacy staff relationships.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
OCTOBER 27, 2022
Because it is ‘off the shelf,’ Tecvayli may have advantages over the CAR-T therapies, which are custom made for each patient and involve harvesting the patient's T cells.
Pharmacy Times
OCTOBER 27, 2022
IMU-935 is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma/truncated.
STAT
OCTOBER 27, 2022
As an oncologist and a leader at a national cancer organization, I’ve watched countless families celebrate the incredible news that their child has defeated a pediatric cancer. But I often don’t have the heart — at least not right away — to tell them what’s coming next: a lifetime of doctor’s visits, health issues, and stress, much of it related to the treatments that were used to ensure their child’s survival.
Pharmacy Times
OCTOBER 27, 2022
Ozanimod is an oral, sphinogosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
The FDA Law Blog
OCTOBER 27, 2022
By Holly N. Brevig, Senior Regulatory Device and Biologics Exper & Richard A. Lewis, Senior Regulatory Device & Biologics Expert — FDA recently published the final guidance document “ Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA.” This final guidance provides recommendations to original applicants and holders of approved applications for human drugs and certain biological products on implementing chemi
pharmaphorum
OCTOBER 27, 2022
The concept of patient centricity has been a key talking point across the healthcare ecosystem for years. Having recognised the tangible benefits that their unique insights and experiences can bring to the table, decision-makers are increasingly seeking new opportunities to partner with patients across a product’s lifecycle. However, fostering lasting and meaningful partnerships is not a simple task for life science companies.
Drug Topics
OCTOBER 27, 2022
The keynote address for the fall 2022 Total Pharmacy Solutions Summit looks at where independent pharmacy is and what needs to be done.
STAT
OCTOBER 27, 2022
Amid sporadic shortages of a drug that is essential in preparing patients for lifesaving, cancer-fighting treatments, one manufacturer has returned to the market — but is selling its medicine for 10 to 20 times the prices offered by the only other companies with available supplies. Over the past week, Areva Pharmaceuticals began marketing vials of fludarabine at a wholesale price of $2,736, a much steeper cost than the $272 charged for the same dosage by Fresenius Kabi and the $109 price
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
DiversifyRx
OCTOBER 27, 2022
Many pharmacy owners will need a source of working capital at some point in their ownership journey. Pharmacy Cash Flow Is Tight. Recently we put up a poll on our LinkedIn and Facebook pages, asking pharmacy owners if they were interested in learning about financing working capital. The overwhelming response was YES, as many pharmacy owners are dealing with tight cash flow, increased costs, etc.
STAT
OCTOBER 27, 2022
Sure, you’ve heard of CRISPR. But it’s 2022. The acronym you need to know now is ADARs. That stands for “adenosine deaminases acting on RNA.” Catchy it may not be. But this RNA-editing class of proteins, made by all multicellular organisms, is starting to have its moment in the bioengineering sun.
pharmaphorum
OCTOBER 27, 2022
Santhera has completed a rolling application for its Duchenne muscular dystrophy (DMD) therapy vamorolone in the US, setting up a possible approval and launch in the latter half of 2023. The Swiss biotech is seeking a priority review for vamorolone, which was licensed from US biotech ReveraGen BioPharma in 2020 after Santhera its former DMD therapy candidate idebenone failed clinical testing and was abandoned.
STAT
OCTOBER 27, 2022
Flooding, heat waves, wildfires, and other climate-driven weather extremes in recent years have catapulted hospitals into emergency mode and devastated the communities they serve, with Hurricane Ian’s deadly rampage through central Florida only the most recent example. But while hospitals might seem to be the unwitting victims of climate disasters, the U.S. health care system — and hospitals in particular — shoulder a good deal of the blame.
pharmaphorum
OCTOBER 27, 2022
On 28 September 2022, the international and European self-regulatory bodies for the research-based pharmaceutical industry ( IFPMA , the International Federation of Pharmaceutical Manufacturers and Associations, and EFPIA , the European Federation of Pharmaceutical Industries and Associations) published a Note for Guidance to assist member companies with their use of social media and digital channels and to help ensure they stay within the regulations on promotion of medicines to the public.
STAT
OCTOBER 27, 2022
The crisis of opioid overdose deaths that sparked the multitude of lawsuits leading to a historic settlement continues to rage, with overdose deaths at an all-time high despite heightened national awareness and more resources than ever dedicated to treatment and overdose prevention. The persistence of this crisis underscores the dire need for well-informed and sustainable solutions that work — and funding for them.
European Pharmaceutical Review
OCTOBER 27, 2022
The Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) has released new data on the US bioscience industry, indicating it was valued at $2.9 trillion dollars in 2021. The report also found that in 2021, the US industry employed 2.1 million people in over 127,000 businesses. The report , developed in partnership by TEConomy Partners and BIO, is the tenth in a biennial series that assesses the state of the US bioscience industry and its innovation s
STAT
OCTOBER 27, 2022
Montana is signaling it might step away from an innovative way of setting the prices its public employee health plan pays hospitals for services, an approach that has saved the state millions of dollars and become a model for health plans nationwide. The plan gained national renown among employers and health care price reform advocates when, in 2016, it established maximum amounts the health plan would pay for all inpatient and outpatient services.
Drug Store News
OCTOBER 27, 2022
Albertsons’ pet offerings provide pharmacy services and pilot healthcare programs to enhance convenience and reduce the financial burden associated with caring for four-legged family members.
STAT
OCTOBER 27, 2022
Can Covid denialism get you elected? How is the music business like biotech investing? And what’s at stake for science in the midterms? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Sarah Owermohle joins us to discuss how pandemic shutdowns, Covid-19 vaccines, and the prospect of arresting Anthony Fauci have become campaign rallying cries in midterm elections.
pharmaphorum
OCTOBER 27, 2022
GSK has said it will not be able to move ahead with regulatory filings for otilimab as a treatment for rheumatoid arthritis (RA), after it failed to show the desired level of efficacy in two phase 3 trials. The phase 3 clinical programme, named ContRAst, was the first in RA to include head-to-head comparisons of otilimab with current treatments, hoping to build a niche for otilimab among hard-to-treat patients who have an inadequate response to or cannot tolerate available drugs.
STAT
OCTOBER 27, 2022
Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of Pumpkin Spice for the occasion. Autumn, after all, is in full swing.
European Pharmaceutical Review
OCTOBER 27, 2022
Elements leading to a rational design of cyclodextrin-based formulations. Cyclodextrins are a frequently used excipient in the pharmaceutical industry, employed in multiple dosage forms and with multiple purposes simply because of their numerous positive properties, including being generally well tolerated and safe. In this short article, René Holm, Professor in pharmaceutical physical chemistry at the University of Southern Denmark, provides a few examples of how a rational formulation design f
pharmaphorum
OCTOBER 27, 2022
Last month, pharmaphorum had the chance to speak with Dr Isabelle Ray-Coquard, professor of medical oncology (specialism sarcomas and GISTs) at the Centre Léon Bérard (CLB), a hospital 100% dedicated to cancer care and research. Discussion was centred around ESMO 2022, where Dr Ray-Coquard presented collated data from a landmark five-year follow-up of the AstraZeneca/MSD PAOLA-1 phase 3 trial, the results from which suggested a clinically meaningful improvement in overall survival rates of certa
Drug Store News
OCTOBER 27, 2022
Doug Long discussed where we are with COVID-19, cough, cold and flu, and RSV, medical claims, telehealth, channels of trade, generics, biosimilars and opioids.
Pharmacy Times
OCTOBER 27, 2022
An expert panel led by moderator Dr. Cunningham identify substance use disorder, COVID-19’s role, and opportunities for pharmacists to help patients with resources for recovery.
PharmaVoice
OCTOBER 27, 2022
Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.
Pharmacy Times
OCTOBER 27, 2022
Completing a breast cancer-focused continuing education credit and encouraging screenings are 2 ways that pharmacists can get involved during the month of October.
Drug Store News
OCTOBER 27, 2022
The Dunkin’ Box O’ Chocolates features two Hot Chocolate Bomb varieties and 12 individually wrapped donut-shaped filled chocolates.
Pharmacy Times
OCTOBER 27, 2022
Strengthening partnerships with healthcare professionals and driving awareness on the clinical benefits of dermatological skincare is the key to success in the public health space.
Expert insights. Personalized for you.
297 
Let's personalize your content